Back to Authors

Sellon, Jacob L

0000-0002-9716-8816

Mayo Clinic

Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA.

Citations 2

Single‐Operator Stress Ultrasound Evaluation of Ulnohumeral Joint Instability Related to Medial Ulnar Collateral Ligament Injury
Kopecky, Benjamin F. , Boettcher, Brennan J. , Sellon, Jacob L. , Camp, Christopher L. , Sellon, Jacob L , Kopecky, Benjamin

Journal of Ultrasound in Medicine | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jum.70391 Get It

This article introduces a novel, single‐operator stress ultrasound technique for evaluating medial ulnar collateral ligament (MUCL) integrity by assessing medial ulnohumeral joint (MUHJ) widening under valgus stress. Unlike prior methods requiring dual operators, specialized equipment, or the use of hand/wrist weights, this approach was designed for clinical efficiency, reproducibility, and patient comfort. By positioning the patient comfortably in a side‐lying position with the elbow flexed to 50°, MUHJ width is measured at baseline (maximally apposed) and manually stressed positions, in a manner that may reduce muscular compensation, avoid viscoelastic creep, and facilitate consistency. While additional research is needed to evaluate clinical feasibility, assess reliability, and compare our technique with previously published methods of dynamic MUCL assessment, the aim of this manuscript is to describe our technique and provide a rationale for its potential utility in musculoskeletal ultrasound practice and research.
Ultrasound-Guided Percutaneous Fasciotomy and Debridement for Chronic Plantar Fasciopathy: Six-Year Patient-Reported Outcomes from a Retrospective Case Series
Ha, Chris Thuc , Romero, J. García , Carta, Karina González , Murthy, Naveen S. , Sellon, Jacob L. , Boettcher, Brennan J. , Ha, Chris , Romero, Joshua M , Gonzalez-Carta, Karina , Murthy, Naveen S , Sellon, Jacob L

Foot & Ankle International | November 3, 2025 | Volume: 46 | Issue: 11 | Pages: 1239-1247

10.1177/10711007251372136 Get It

Background: Ultrasound-guided percutaneous fasciotomy and debridement (USPFD) is a minimally invasive treatment for patients with plantar fasciopathy refractory to conservative management. Previous studies have shown clinical improvement with USPFD, but pain relief and patient satisfaction have not been demonstrated beyond 2 years. Methods: This retrospective case series included patients who underwent USPFD at a quaternary academic medical center between April 2013 and January 2018, with refractory plantar fasciopathy and at least 4 years’ follow-up. Patient outcomes were assessed through electronic surveys and telephone interviews. Primary outcome measures included mean changes in visual analog scale pain (VAS-Pain) scores and patient satisfaction via Likert scale. Secondary measures included VAS-Pain with the first 5 steps, VAS-Pain during daily weightbearing, and procedural complications. Results: Seventy unique procedures were identified among 62 patients. Follow-up data were obtained from 51 of 62 patients (82%) who responded to surveys or phone calls. This corresponded to 58 of 70 procedures (83%) at a mean postprocedure follow-up of 6.6 ± 1.4 years. Patients had a mean duration of symptoms of 2.1 ± 3.0 years prior to the procedure. Baseline VAS-Pain was 6.8 ± 2.2 and final follow-up VAS-Pain was 0.7 ± 1.1. At the last follow-up, patient-reported VAS-Pain with first 5 steps was 0.9 ± 1.6 and VAS-Pain with weightbearing through the day was 1.3 ± 1.8. Overall, 91% (53/58) of the procedures were considered successful, where patients responded they were “satisfied” or “very satisfied” and 52 of 58 (90%) procedural responses indicated that based on the outcome, they would recommend the procedure to others. Final follow-up VAS-Pain, VAS-first 5 steps, and VAS-weightbearing, were all improved in the success vs failure groups ( P ≤ .002). No complications were reported. Conclusion: USPFD was associated with high patient satisfaction and durable pain relief for chronic plantar fasciopathy at an average follow-up of 6.6 ± 1.4 years.